BACKGROUND: Studies report mixed findings regarding antidepressant agents and suicide risks, and few examine suicide deaths. Studies using observational data can accrue the large sample sizes needed to examine suicide death, but selection biases must be addressed. We assessed associations between suicide death and treatment with the 7 most commonly used antidepressants in a national sample of Department of Veterans Affairs patients in depression treatment. Multiple analytic strategies were used to address potential selection biases. METHODS: We identified Department of Veterans Affairs patients with depression diagnoses and new antidepressant starts between April 1, 1999, and September 30, 2004 (N = 502,179). Conventional Cox regression models, Cox models with inverse probability of treatment weighting, propensity-stratified Cox models, marginal structural models (MSM), and instrumental variable analyses were used to examine relationships between suicide and exposure to bupropion, citalopram, fluoxetine, mirtazapine, paroxetine, sertraline, and venlafaxine. RESULTS: Crude suicide rates varied from 88 to 247 per 100,000 person-years across antidepressant agents. In multiple Cox models and MSMs, sertraline and fluoxetine had lower risks for suicide death than paroxetine. Bupropion had lower risks than several antidepressants in Cox models but not MSMs. Instrumental variable analyses did not find significant differences across antidepressants. DISCUSSION: Most antidepressants did not differ in their risk for suicide death. However, across several analytic approaches, although not instrumental variable analyses, fluoxetine and sertraline had lower risks of suicide death than paroxetine. These findings are congruent with the Food and Drug Administration meta-analysis of randomized controlled trials reporting lower risks for "suicidality" for sertraline and a trend toward lower risks with fluoxetine than for other antidepressants. Nevertheless, divergence in findings by analytic approach suggests caution when interpreting results.
BACKGROUND: Studies report mixed findings regarding antidepressant agents and suicide risks, and few examine suicide deaths. Studies using observational data can accrue the large sample sizes needed to examine suicide death, but selection biases must be addressed. We assessed associations between suicide death and treatment with the 7 most commonly used antidepressants in a national sample of Department of Veterans Affairs patients in depression treatment. Multiple analytic strategies were used to address potential selection biases. METHODS: We identified Department of Veterans Affairs patients with depression diagnoses and new antidepressant starts between April 1, 1999, and September 30, 2004 (N = 502,179). Conventional Cox regression models, Cox models with inverse probability of treatment weighting, propensity-stratified Cox models, marginal structural models (MSM), and instrumental variable analyses were used to examine relationships between suicide and exposure to bupropion, citalopram, fluoxetine, mirtazapine, paroxetine, sertraline, and venlafaxine. RESULTS: Crude suicide rates varied from 88 to 247 per 100,000 person-years across antidepressant agents. In multiple Cox models and MSMs, sertraline and fluoxetine had lower risks for suicide death than paroxetine. Bupropion had lower risks than several antidepressants in Cox models but not MSMs. Instrumental variable analyses did not find significant differences across antidepressants. DISCUSSION: Most antidepressants did not differ in their risk for suicide death. However, across several analytic approaches, although not instrumental variable analyses, fluoxetine and sertraline had lower risks of suicide death than paroxetine. These findings are congruent with the Food and Drug Administration meta-analysis of randomized controlled trials reporting lower risks for "suicidality" for sertraline and a trend toward lower risks with fluoxetine than for other antidepressants. Nevertheless, divergence in findings by analytic approach suggests caution when interpreting results.
Authors: Sebastian Schneeweiss; Amanda R Patrick; Daniel H Solomon; Colin R Dormuth; Matt Miller; Jyotsna Mehta; Jennifer C Lee; Philip S Wang Journal: Pediatrics Date: 2010-04-12 Impact factor: 7.124
Authors: Jeremy A Rassen; M Alan Brookhart; Robert J Glynn; Murray A Mittleman; Sebastian Schneeweiss Journal: J Clin Epidemiol Date: 2009-04-08 Impact factor: 6.437
Authors: Marcin Wojnar; Mark A Ilgen; Julita Wojnar; Ryan J McCammon; Marcia Valenstein; Kirk J Brower Journal: J Psychiatr Res Date: 2008-09-07 Impact factor: 4.791
Authors: Marc Stone; Thomas Laughren; M Lisa Jones; Mark Levenson; P Chris Holland; Alice Hughes; Tarek A Hammad; Robert Temple; George Rochester Journal: BMJ Date: 2009-08-11
Authors: Robert D Gibbons; Marcelo Coca Perraillon; Kwan Hur; Rena M Conti; Robert J Valuck; David A Brent Journal: Pharmacoepidemiol Drug Saf Date: 2014-09-29 Impact factor: 2.890
Authors: Kara Zivin; H Myra Kim; Matheos Yosef; Donovan T Maust; Marcia Valenstein; Eric G Smith; Dimitry S Davydow Journal: J Clin Psychopharmacol Date: 2016-10 Impact factor: 3.153
Authors: Hyungjin Myra Kim; Kara Zivin; Hae Mi Choe; Clare M Stano; Dara Ganoczy; Heather Walters; Marcia Valenstein Journal: J Manag Care Spec Pharm Date: 2015-05
Authors: Yi Chai; Hao Luo; Kenneth K C Man; Wallis C Y Lau; Sherry K W Chan; Paul S F Yip; Ian C K Wong Journal: Lancet Reg Health West Pac Date: 2022-08-10